Published in Vaccine on August 06, 2013
Immunogenicity of Influenza Vaccine in Long Term Care | NCT02933723
FLUAD vs. FLUZONE HD Influenza Vaccine in Residents of Long Term Care | NCT03694808
Potential of the test-negative design for measuring influenza vaccine effectiveness: a systematic review. Expert Rev Vaccines (2014) 1.25
Selection bias in the comparison between adjuvanted and unadjuvanted influenza vaccine effectiveness. Vaccine (2013) 1.07
Influenza symptoms and their impact on elderly adults: randomised trial of AS03-adjuvanted or non-adjuvanted inactivated trivalent seasonal influenza vaccines. Influenza Other Respir Viruses (2014) 0.90
The life cycle of a T cell after vaccination - where does immune ageing strike? Clin Exp Immunol (2016) 0.82
Influenza vaccines: unmet needs and recent developments. Infect Chemother (2013) 0.81
Influenza Vaccination of Healthcare Workers: Critical Analysis of the Evidence for Patient Benefit Underpinning Policies of Enforcement. PLoS One (2017) 0.79
Reply to letter to the editor. Vaccine (2015) 0.75
Immunization in Canada: Update for 2015. J Can Chiropr Assoc (2016) 0.75
Requirements of New Vaccines against Novel Influenza Viruses. Trop Med Health (2014) 0.75
Influenza vaccination and the end of simplicity. Dtsch Arztebl Int (2013) 0.75
Synthetic TLR4 and TLR7 ligands work additively via MyD88 to induce protective antiviral immunity in mice. J Virol (2017) 0.75
Innovative endpoint determination system for antifungal susceptibility testing of yeasts. Antimicrob Agents Chemother (1992) 3.09
Pseudomonas cepacia in lung transplant recipients with cystic fibrosis. Chest (1993) 2.58
The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. J Viral Hepat (2014) 2.23
Evaluation of Roche Amplicor PCR assay for Mycobacterium tuberculosis. J Clin Microbiol (1996) 1.70
Infection with Burkholderia cepacia in cystic fibrosis: outcome following lung transplantation. Am J Respir Crit Care Med (2001) 1.69
Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents. J Viral Hepat (2009) 1.69
Historical epidemiology of hepatitis C virus (HCV) in selected countries. J Viral Hepat (2014) 1.68
Clinical utility of quantitative cytomegalovirus viral load determination for predicting cytomegalovirus disease in liver transplant recipients. Transplantation (1999) 1.67
Strategies to manage hepatitis C virus (HCV) disease burden. J Viral Hepat (2014) 1.67
Interim estimates of 2014/15 vaccine effectiveness against influenza A(H3N2) from Canada's Sentinel Physician Surveillance Network, January 2015. Euro Surveill (2015) 1.50
Exploring differences in response to treatment with peginterferon alpha 2a (40kD) and ribavirin in chronic hepatitis C between genotypes 2 and 3. J Viral Hepat (2008) 1.45
Protective effect of single-dose adjuvanted pandemic influenza vaccine in children. Influenza Other Respir Viruses (2010) 1.32
No association between hepatitis C and B-cell lymphoma. Hepatology (1999) 1.28
Detection of occult low-grade b-cell non-Hodgkin's lymphoma in patients with chronic hepatitis C infection and mixed cryoglobulinemia. Hepatology (1999) 1.26
Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy. Gut (2006) 1.22
Outbreak of mumps among young adults--Vancouver, British Columbia. Can Commun Dis Rep (1997) 1.22
Approaches to the detection of enteric pathogens, including Campylobacter, using nucleic acid hybridization. Diagn Microbiol Infect Dis (1986) 1.18
Interim estimates of influenza vaccine effectiveness in 2012/13 from Canada's sentinel surveillance network, January 2013. Euro Surveill (2013) 1.18
Assessment of in-flight transmission of SARS--results of contact tracing, Canada. Can Commun Dis Rep (2003) 1.11
Treating chronic hepatitis C with pegylated interferon alfa-2a (40 KD) and ribavirin in clinical practice. Aliment Pharmacol Ther (2006) 1.07
Molecular typing of Stenotrophomonas (Xanthomonas) maltophilia by DNA macrorestriction analysis and random amplified polymorphic DNA analysis. J Clin Microbiol (1995) 1.07
Public health and hepatitis C. Can J Public Health (2000) 1.04
Impact of hepatitis C virus infection on all-cause and liver-related mortality in a large community-based cohort of inner city residents. J Viral Hepat (2011) 1.02
Interim estimates of 2013/14 vaccine effectiveness against influenza A(H1N1)pdm09 from Canada s sentinel surveillance network, January 2014. Euro Surveill (2014) 1.00
A multicenter study evaluation of the digene hybrid capture II signal amplification technique for detection of hepatitis B virus DNA in serum samples and testing of EUROHEP standards. J Clin Microbiol (2000) 0.99
Antenatal seroprevalence of herpes simplex virus type 2 (HSV-2) in Canadian women: HSV-2 prevalence increases throughout the reproductive years. Sex Transm Dis (2001) 0.97
Adenovector-mediated gene delivery of interleukin-2 in metastatic breast cancer and melanoma: results of a phase 1 clinical trial. Gene Ther (1999) 0.95
Investigation of a multiyear multiple critical care unit outbreak due to relatively drug-sensitive Acinetobacter baumannii: risk factors and attributable mortality. J Infect Dis (1996) 0.95
Primary cervical cancer screening with HPV testing compared with liquid-based cytology: results of round 1 of a randomised controlled trial -- the HPV FOCAL Study. Br J Cancer (2012) 0.95
Cardiovascular manifestations of Lyme disease. Am Heart J (1991) 0.94
Clinical utility of viral load measurements in individuals with chronic hepatitis C infection on antiviral therapy. J Viral Hepat (2005) 0.93
Self-collection of genital human papillomavirus specimens in heterosexual men. Sex Transm Infect (2008) 0.91
Evaluation of the Merifluor immunofluorescent assay for the detection of Cryptosporidium and Giardia in sodium acetate formalin-fixed stools. Diagn Microbiol Infect Dis (1994) 0.91
Toll-like receptors 2 and 4 and the cryopyrin inflammasome in normal pregnancy and pre-eclampsia. BJOG (2010) 0.90
High-performance liquid chromatography to assess the effect of serum storage conditions on the detection of hepatitis C virus by the polymerase chain reaction. J Virol Methods (1993) 0.90
A pilot study of ribavirin therapy for recurrent hepatitis C virus infection after liver transplantation. Transplantation (1996) 0.89
Hepatitis C virus infection in patients infected with the human immunodeficiency virus. Clin Infect Dis (1993) 0.88
Genotype D amongst injection drug users with acute hepatitis B virus infection in British Columbia. J Viral Hepat (2009) 0.86
Efficacy and safety of 5-mm-diameter bipolar and ultrasonic shears for cutting carotid arteries of the hybrid pig. Surg Endosc (2010) 0.86
Clinical practice guidelines: prevention of cytomegalovirus disease after renal transplantation. J Am Soc Nephrol (1998) 0.86
An outbreak of mumps among young adults in Vancouver, British Columbia, associated with 'rave' parties. Can J Public Health (1999) 0.84
Polymerase chain reaction kinetics when using a positive internal control target to quantitatively detect cytomegalovirus target sequences. J Virol Methods (1994) 0.84
Case of vaccine-associated measles five weeks post-immunisation, British Columbia, Canada, October 2013. Euro Surveill (2013) 0.83
Does measles-mumps-rubella (MMR) vaccination cause inflammatory bowel disease and autism? Can Commun Dis Rep (2001) 0.83
Clinical trial: exposure to ribavirin predicts EVR and SVR in patients with HCV genotype 1 infection treated with peginterferon alpha-2a plus ribavirin. Aliment Pharmacol Ther (2008) 0.83
Successful treatment of juvenile laryngeal papillomatosis-related multicystic lung disease with cidofovir: case report and review of the literature. Chest (2000) 0.82
Detection of hepatitis C virus in the corneas of seropositive donors. Cornea (2001) 0.81
Efficient adenovirus-mediated gene expression in malignant human plasma cells: relative lymphoid cell resistance. Exp Hematol (1998) 0.81
Re-treatment with peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have relapsed or not responded to a first course of pegylated interferon-based therapy. Can J Gastroenterol (2009) 0.81
Modelling the costs and effects of a universal infant immunization program using conjugated pneumococcal vaccine in British Columbia. Can Commun Dis Rep (2003) 0.81
Quaternary structure of V1 and F1 ATPase: significance of structural homologies and diversities. Biochemistry (1998) 0.80
Hepatitis A virus seroprevalence in 1,000 university students in Toronto. Can Commun Dis Rep (2001) 0.79
Population-based evaluation of type-specific HPV prevalence among women in British Columbia, Canada. Vaccine (2012) 0.79
Oral prostaglandin (PGE2) therapy for chronic viral hepatitis B and C. J Viral Hepat (1999) 0.79
The relationship between hirudin and activated clotting time: implications for patients with heparin-induced thrombocytopenia undergoing cardiac surgery. Anesth Analg (2001) 0.79
Outcome of long-term ribavirin therapy for recurrent hepatitis C after liver transplantation. Transplantation (1999) 0.79
Cytomegalovirus viremia in lung transplant recipients receiving ganciclovir and immune globulin. Chest (1998) 0.78
Long-term predictive value of a single cytomegalovirus (CMV) DNA PCR assay for CMV disease in human immunodeficiency virus-infected patients. J Clin Microbiol (1998) 0.77
Quantification of polymerase chain reaction products in agarose gels with a fluorescent europium chelate as label and time-resolved fluorescence spectroscopy. Anal Chem (1993) 0.77
Relation between hospital HIV/AIDS caseload and mortality among persons with HIV/AIDS in Canada. Clin Invest Med (1998) 0.77
A phase I study of adenovirus mediated gene transfer of interleukin 2 cDNA into metastatic breast cancer or melanoma. Hum Gene Ther (1997) 0.77
Continuous flow perfusion of gentamicin with a scleral shell reduces bacterial colony counts in experimental Pseudomonas keratitis. J Ocul Pharmacol (1993) 0.76
Epidemiologic profile of a new H3N2 variant of influenza A mismatched to vaccine, 2003-2004 influenza season. Can Commun Dis Rep (2005) 0.76
Polymerase chain reaction based assessment of leukoreduction efficacy using a cytomegalovirus DNA transfected human T-cell line. J Clin Virol (1998) 0.76
Hepatitis C and HIV prevalence using oral mucosal transudate, and reported drug use and sexual behaviours of youth in custody in British Columbia. Can J Public Health (2009) 0.76
Long-term ribavirin therapy for recurrent hepatitis C after liver transplantation. Transplant Proc (1997) 0.76
Hepatitis. Can J Infect Dis (2001) 0.75
The effect of epsilon-aminocaproic acid on HemoSTATUS and kaolin-activated clotting time measurements. Anesth Analg (2000) 0.75
Clinical evaluation of a new, point-of-care hemocytometer. Crit Care Med (2000) 0.75
Unusual manifestation of esophageal foreign body. Can Med Assoc J (1985) 0.75
Acquired peanut hypersensitivity following platelet transfusion. Transfus Med (2014) 0.75
Long term follow-up of patients with chronic hepatitis C treated with interferon alpha. Can J Gastroenterol (2000) 0.75
Long-term follow-up of a randomized trial of interferon therapy for chronic hepatitis B in a predominantly homosexual male population. J Hepatol (1999) 0.75
Continuous flow contact lens delivery of gentamicin to rabbit cornea and aqueous humor. J Ocul Pharmacol (1992) 0.75
Invasive group A streptococcus in two siblings: a case for antibiotic prophylaxis of close contacts. Can Commun Dis Rep (2001) 0.75
[Chronic arterial occlusive disease: early and late results after semi-ambulatory treatment with serpent enzyme (Arvin)]. Vasa (1979) 0.75
Durability of serological remission in chronic hepatitis C treated with interferon-alpha-2B. Am J Gastroenterol (1998) 0.75
Vox Sanguinis International Forum on donor notification and counselling strategies for markers of transfusion-transmissible infections: summary. Vox Sang (2017) 0.75
Hepatitis C surveillance--are we doing enough? British Columbia, 2001. Can Commun Dis Rep (2002) 0.75
Regional distribution of opioidergic nerves in human and canine prostates. Prostate (1989) 0.75